Prevalence of Tardive Dyskinesia and Its Association with Antipsychotic Drug and Depression in Geriatric Population in Lahore, Pakistan: Tardive Dyskinesia’s Association with Antipsychotic Drug and Depression

Maria Mustafa; Kanzul Kamal; . Irsa; . Minahil; Laiba Azam; Aira Eman

doi:10.54393/pjhs.v6i1.1990

Authors

Maria Mustafa Department of Physical Medicine and Rehabilitation, School of Health Sciences, University of Management and Technology, Lahore, Pakistan
Kanzul Kamal Department of Physical Medicine and Rehabilitation, School of Health Sciences, University of Management and Technology, Lahore, Pakistan
. Irsa Department of Physical Medicine and Rehabilitation, School of Health Sciences, University of Management and Technology, Lahore, Pakistan
. Minahil Department of Physical Medicine and Rehabilitation, School of Health Sciences, University of Management and Technology, Lahore, Pakistan
Laiba Azam Department of Physical Medicine and Rehabilitation, School of Health Sciences, University of Management and Technology, Lahore, Pakistan
Aira Eman Department of Physical Medicine and Rehabilitation, School of Health Sciences, University of Management and Technology, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i1.1990

Keywords:

Tardive Dyskinesia, Depression, Antipsychotic Drugs, Geriatric Population, Sero-Prevalence

Abstract

“Tardive Dyskinesia” is the subtle onset of rhythmic, stereotype, repetitive movement of the face, mouth, and tongue. The basic pathology behind this disease is hypersensitization of dopamine receptors. Objective: To find out the prevalence of tardive dyskinesia and its association with depression and antipsychotic drug administration in the geriatric population. Methods: A cross-sectional descriptive study was conducted for a period of four months from February 2023 to May 2023. The data were collected from different hospital settings in Lahore. A sample size of 150 elderly individuals aged 55-80 years were included. Depression was evaluated through Geriatric Depression Scale whereas abnormal involuntary movement Tardive Dyskinesia is evaluated through AIMS scale. Chi square test was used to determine the association between variables Depression, Antipsychotic drug and Tardive Dyskinesia. Informed consent and ethical approval were taken from all participants. Results: Out of 150 respondents, 78 (52%) male and 72 (48%) were female. Mean age was 65 years ± 7.21 SD. Among all individuals 20% experienced mild, 42.7% with moderate and 37.3% experienced severe depression.27.3% of the population taking antipsychotic drug experienced Tardive dyskinesia while it was absent in 22.67% of the individuals who were taking antipsychotic drug.20.67% of old individuals with severe depression were with Tardive dyskinesia. Conclusions: It is concluded from above study depression is common among geriatric population. Antidepressant drugs used to treat depression for longer duration because abnormal movement called tardive dyskinesia. There is significant relation of Tardive Dyskinesia with depression and antipsychotic drugs.

References

Factor SA. Management of tardive syndrome: medications and surgical treatments. Neurotherapeutics. 2020 Oct; 17(4): 1694-712. doi: 10.1007/s13311-020-00898-3.

Owens DC. Tardive dyskinesia update: the syndrome. BJPsych Advances. 2019 Jan; 25(1): 57-69. doi: 10.1192/bja.2018.45.

Ricciardi L, Pringsheim T, Barnes TR, Martino D, Gardner D, Remington G et al. Treatment recommendations for tardive dyskinesia. The Canadian Journal of Psychiatry. 2019 Jun; 64(6): 388-99. doi: 10.1177/0706743719828968.

Ward KM and Citrome L. Antipsychotic-related movement disorders: drug-induced Parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurology and Therapy. 2018 Dec; 7: 233-48. doi: 10.1007/s40120-018-0105-0.

Frei K. Tardive dyskinesia: Who gets it and why. Parkinsonism & Related Disorders. 2019 Feb; 59: 151-4. doi: 10.1016/j.parkreldis.2018.11.017.

Takeuchi H, Mori Y, Tsutsumi Y. Pathophysiology, prognosis and treatment of tardive dyskinesia. Therapeutic Advances in Psychopharmacology. 2022 Oct; 12: 20451253221117313. doi: 10.1177/20451253221117313.

Caroff SN. A new era in the diagnosis and treatment of tardive dyskinesia. CNS Spectrums. 2023 Aug; 28(4): 401-15. doi: 10.1017/S1092852922000992.

Kane JM, Correll CU, Nierenberg AA, Caroff SN, Sajatovic M, Tardive Dyskinesia Assessment Working Group. Revisiting the abnormal involuntary movement scale: proceedings from the tardive dyskinesia assessment workshop. The Journal of Clinical Psychiatry. 2018 May; 79(3): 18344. doi: 10.4088/JCP.17cs11959.

Hauser RA, Meyer JM, Factor SA, Comella CL, Tanner CM, Xavier RM et al. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectrums. 2022 Apr; 27(2): 208-17. doi: 10.1017/S109285292000200X.

Niemann N and Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018 Apr; 78: 525-41. doi: 10.1007/s40265-018-0874-x.

Scorr LM and Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. Journal of the Neurological Sciences. 2018 Jun; 389: 43-7. doi: 10.1016/j.jns.2018.02.006.

Zalyalova ZA. [Tardive dyskinesia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2023; 123(7): 25-31. doi: 10.17116/jnevro202312307125.

Szczakowska A, Gabryelska A, Gawlik-Kotelnicka O, Strzelecki D. Deep brain stimulation in the treatment of tardive dyskinesia. Journal of Clinical Medicine. 2023 Feb; 12(5): 1868. doi: 10.3390/jcm12051868.

Farber RH, Stull DE, Witherspoon B, Evans CJ, Yonan C, Bron M et al. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. Journal of Patient-Reported Outcomes. 2024 Jan; 8(1): 2. doi: 10.1186/s41687-023-00679-4.

Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S. Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States. Journal of Patient-Reported Outcomes. 2023 Nov; 7(1): 122. doi: 10.1186/s41687-023-00658-9.

Tanner CM, Caroff SN, Cutler AJ, Lenderking WR, Shalhoub H, Pagé V et al. Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study. Journal of Patient-Reported Outcomes. 2023 Mar; 7(1): 21. doi: 10.1186/s41687-023-00551-5.

Kumsa A, Girma S, Alemu B, Agenagnew L. Psychotropic medications-induced tardive dyskinesia and associated factors among patients with mental illness in Ethiopia. Clinical Pharmacology: Advances and Applications. 2020 Dec: 179-87. doi: 10.2147/CPAA.S285585.

Jackson R, Brams MN, Carlozzi NE, Citrome L, Fritz NE, Hoberg AR et al. Impact-tardive dyskinesia (impact-TD) scale: a clinical tool to assess the impact of tardive dyskinesia. The Journal of Clinical Psychiatry. 2022 Nov; 84(1): 44284. doi: 10.4088/JCP.22cs14563.

Patterson-Lomba O, Ayyagari R, Carroll B. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BioMed Central Neurology. 2019 Dec; 19: 1-0. doi: 10.1186/s12883-019-1385-4.

Citrome L, Isaacson SH, Larson D, Kremens D. Tardive dyskinesia in older persons taking antipsychotics. Neuropsychiatric Disease and Treatment. 2021 Oct: 3127-34. doi: 10.2147/NDT.S328301